Leadership
The Neuropathix leadership team has more than 40 years of business, marketing and drug development experience with Fortune 500, Pharma and leading Biotechnology firms. Our scientific team, Board of Directors and Scientific Advisory Board are comprised of dedicated business professionals, clinicians and bio-chemists, all have a strong background in phyto-medical, biological and pharmaceutical sciences with a long track record of successful drug development and identifying phyto-medicine and therapeutics that are complex in nature and structure. Overall, the Neuropathix scientific team has over 75+ years of research and pharmaceutical experience and have been published in over 300 notable journal publications and jointly hold over 65 patents.
Executive Team
Dean Petkanas
Chairman & CEO
William A. Kinney, PhD
Chief Scientific Officer
Thoma Kikis
Founder / Chief Communications Officer, Board Director
Mark Corrao
Chief Financial Officer
Mark McDonnell, PhD
Chief Chemist
Douglas Brenneman, PhD
Chief Pharmacologist
Board of Directors
Dean Petkanas
Chairman & CEO
Thoma Kikis
Founder / Chief Communications Officer, Board Director
Robert Malasek
Director
Blake Schroeder
Board Director
Timothy Scott, PhD
Board Director
Scientific Advisory Board
Tage Honoré, Phd, DSc
Chairman of Scientific Advisory Board
Sara Jane Ward, PhD
Scientific Advisory Board
Daniele Piomelli, PhD, MD
Scientific Advisory Board
Charles L. Loprinzi, MD
Scientific Advisory Board
Michael Ropacki, PhD
Scientific Advisory Board
Tyler Sexton, MD
Scientific Advisory Board
Daniel Richman, MD
Scientific Advisory Board
Terrence O. Tormey
Company Advisory Board
